Kinect-based objective assessment of the acute levodopa challenge test in parkinsonism: a feasibility study

Neurol Sci. 2024 Jun;45(6):2661-2670. doi: 10.1007/s10072-023-07296-5. Epub 2024 Jan 6.

Abstract

Introduction: The acute levodopa challenge test (ALCT) is an important and valuable examination but there are still some shortcomings with it. We aimed to objectively assess ALCT based on a depth camera and filter out the best indicators.

Methods: Fifty-nine individuals with parkinsonism completed ALCT and the improvement rate (IR, which indicates the change in value before and after levodopa administration) of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS III) was calculated. The kinematic features of the patients' movements in both the OFF and ON states were collected with an Azure Kinect depth camera.

Results: The IR of MDS-UPDRS III was significantly correlated with the IRs of many kinematic features for arising from a chair, pronation-supination movements of the hand, finger tapping, toe tapping, leg agility, and gait (rs = - 0.277 ~ - 0.672, P < 0.05). Moderate to high discriminative values were found in the selected features in identifying a clinically significant response to levodopa with sensitivity, specificity, and area under the curve (AUC) in the range of 50-100%, 47.22%-97.22%, and 0.673-0.915, respectively. The resulting classifier combining kinematic features of toe tapping showed an excellent performance with an AUC of 0.966 (95% CI = 0.922-1.000, P < 0.001). The optimal cut-off value was 21.24% with sensitivity and specificity of 94.44% and 87.18%, respectively.

Conclusion: This study demonstrated the feasibility of measuring the effect of levodopa and objectively assessing ALCT based on kinematic data derived from an Azure Kinect-based system.

Keywords: Depth camera; Levodopa challenge test; Objective assessment; Parkinsonism.

MeSH terms

  • Aged
  • Antiparkinson Agents* / administration & dosage
  • Antiparkinson Agents* / therapeutic use
  • Biomechanical Phenomena / physiology
  • Feasibility Studies*
  • Female
  • Humans
  • Levodopa* / administration & dosage
  • Levodopa* / pharmacology
  • Levodopa* / therapeutic use
  • Male
  • Middle Aged
  • Parkinsonian Disorders* / diagnosis
  • Parkinsonian Disorders* / drug therapy
  • Parkinsonian Disorders* / physiopathology
  • Severity of Illness Index

Substances

  • Levodopa
  • Antiparkinson Agents